Fate Therapeutics (NASDAQ:FATE) Given New $3.00 Price Target at Stifel Nicolaus
Fate Therapeutics (NASDAQ:FATE – Get Free Report) had its price target reduced by equities researchers at Stifel Nicolaus from $5.00 to $3.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has a “hold” rating on the biopharmaceutical company’s stock. Stifel Nicolaus’ target price would indicate a potential upside of 197.03% from […]
Fate Therapeutics (NASDAQ:FATE – Get Free Report) had its price target reduced by equities researchers at Stifel Nicolaus from $5.00 to $3.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has a “hold” rating on the biopharmaceutical company’s stock. Stifel Nicolaus’ target price would indicate a potential upside of 197.03% from […]
